|
|
|
|
Support Care Cancer 2009,Sep,01;17(9):1187-93; (PMID: 19205754) [FULL TEXT AVAILABLE]
[...]vomiting, on the pharmacokinetics of the commonly prescribed 5-hydroxytryptamine receptor 3 receptor antagonists, dolasetron or granisetron. MATERIALS AND METHODS: In a phase I, open-label, two-part, two-period, single-sequence study, two cohorts of healthy subjects received either oral [...]
|
|
|
Lancet Oncol 2009,Feb,01;10(2):115-24; (PMID: 19135415)
[...] is a second-generation 5-hydroxytryptamine 3 (5-HT(3))-receptor antagonist that has shown better efficacy than ondansetron and dolasetron in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy, and similar efficacy to [...]
|
|
|
Curr Drug Saf 2009,Jan,01;4(1):62-73; (PMID: 19149526)
[...], and midazolam. Serotonin receptor antagonists, which include ondansetron, granisetron, tropisetron, dolasetron, and ramosetron, are more effective than traditional antiemetics. However, these drugs are not entirely effective, perhaps because most of them act through the blockade on one type of receptor.[...]
|
|
|
Drugs 2009,Jan,01;69(16):2257-78; (PMID: 19852528)
[...]palonosetron was noninferior to intravenous ondansetron (with statistically greater efficacy than ondansetron) or dolasetron in preventing CINV following MEC, or to intravenous ondansetron or granisetron in preventing CINV following HEC, in the acute phase.[...]
|
|
|
Clin Pharmacokinet 2009,Jan,01;48(12):761-804; (PMID: 19902987)
[...], and proper dose adjustment may be needed when the CYP2D6 genotype is determined in a patient. Dolasetron, ondansetron and tropisetron, all in part metabolized by CYP2D6, are less effective in UMs than in other [...]
|
|
|
Emerg Med J 2008,Oct,01;25(10):706; author reply 706; (PMID: 18843085)
|
|
|
Support Care Cancer 2008,Sep,01;16(9):1011-5; (PMID: 18239945)
[...]OBJECTIVES: The 5-hydroxytryptamine 3 receptor antagonists, including tropisetron, ondansetron, granisetron, and dolasetron are agents used effectively for supportive care. They are used for the prevention and treatment of [...]
|
|
|
J Clin Anesth 2008,Sep,01;20(6):478; (PMID: 18929294)
|
|
|
J Nucl Med 2008,Apr,01;49(4):546-9; (PMID: 18344428)
[...] therapy, would reduce salivary symptoms. All patients received 8 mg of dexamethasone and 100 mg of dolasetron mesylate orally 2 h before therapy and every 12 h for another 5 doses after 131I[...]
|
|
|
J Craniomaxillofac Surg 2008,Apr,01;36(3):173-9; (PMID: 18353666)
INTRODUCTION: The aim of this study was to evaluate the efficacy of dolasetron and droperidol (DHB) for preventing postoperative nausea and vomiting (PONV) in patients undergoing surgery for [...]
|
 1 2 3 4 5 6 7 8 
|
|
